Guggenheim 3rd Annual Healthcare Innovation Conference - PROKIDNEY CORP

Financial Performance:

• No specific revenue, earnings, or profit margin figures disclosed, consistent with a pre-commercial late-stage clinical company.
• Cash position stands at $142 million as of September, sufficient to fund operations through mid-2027.
• Manufacturing capacity at launch (Winston-Salem facility) is 350 patients, expanding to 850 in Year 2 and 1,350 in Year 3, with a 4-year target of 3,000 patients annually.
• No debt mentioned; capital strategy focuses on self-funding through the accelerated readout.

Guidance and Future Outlook:

• Enrollment for the Phase 3 trial (PARCEL) is ongoing but recruitment has stopped; final enrollment expected in Q1 2027.
• Accelerated approval data readout expected in Q2 2027 based on the EGFR slope endpoint.
• Confirmatory endpoint (time to composite event of dialysis, transplant, or death) will be collected in the same study post-accelerated approval.
• Commercial launch strategy involves a focused rollout to 8–10 "Renal Partnership Network" centers of excellence in the U.S. before expanding.
• Management targets a U.S.-only commercial focus initially due to the large addressable market, remaining open to international strategic partnerships later.

Business Segments and Product Lines:

• Primary asset is Roparinsel (autologous cell therapy), a single-product company focused on stabilizing kidney function in advanced CKD and diabetes.
• Therapy mechanism: Cells harvested via kidney biopsy, expanded ex vivo, and re-injected into kidneys (ipsilateral and contralateral).
• Phase 3 protocol focuses on high-risk patients with GFR 20–35 and Type 2 diabetes on standard of care (RAS inhibitors, SGLT2 inhibitors).
• Manufacturing utilizes a viral-vector-free, non-genetic modification process, allowing for outpatient administration without immunosuppression.
• Strong intellectual property position with protected know-how on material and manufacturing processes.

Market and Competitive Landscape:

• Target Total Addressable Market (TAM) includes over 1.1 million U.S. patients with Stage 3b/4 CKD and Type 2 diabetes.
• Addresses a critical unmet need where patients continue to progress to dialysis despite optimized standard of care (SGLT2s, GLP-1s).
• First cell therapy in nephrology; no direct competitors in the pipeline for this specific mechanism in this population.
• Market tailwinds include bipartisan policy support for kidney health (e.g., HHS Kidney Care Plan) and recent FDA RMAT designation.

Risks and Challenges:

• Commercial success hinges on confirming the 50% difference in EGFR slope (1.5 vs 3.0 mL/min decline) in the control group.
• Manufacturing scalability remains a critical path; failure to hit the 3,000-patient/year capacity target could limit growth.
• Patient identification and referral pathways require robust execution to establish the "Renal Partnership Network."
• Pricing strategy is still under development; must align with cell therapy benchmarks while addressing payer value regarding dialysis avoidance.

Management Commentary and Tone:

• Tone is highly confident, characterized by a "single purpose" narrative centered on giving patients hope to avoid dialysis.
• Management expresses strong conviction in the clinical data, citing a 78% improvement in kidney function decline slope from Phase 2 data.
• CEO Bruce Culleton and CCO Greg Madison emphasized the "outpatient-friendly" nature of the therapy compared to other complex cell therapies.
• Team emphasized that the product is positioned to be used "on top of" standard of care rather than replacing it, mitigating concerns about patient displacement.

Analyst Questions and Answers:

• Mechanism of Action: Management confirmed the therapy induces cytoprotective effects, reduces oxidative damage/inflammation, promotes vascular integrity, and stimulates new blood vessel formation in injected areas.
• Comparator Data: Phase 3 assumes a conservative 3 mL/min/year decline in the control group (actual Phase 2 was closer to 6 mL/min), aiming for a 1.5 mL/min/year decline in the treatment arm.
• Standard of Care Interaction: Randomization is stratified by baseline SGLT2 use; the product is designed for patients progressing despite optimal therapy including SGLT2, GLP-1, and RAS inhibitors.
• Commercialization Lessons: Differentiation from failed cell therapies includes no viral vectors (lower complexity/cost), no immunosuppression, and a massive, identifiable U.S. patient population.
• Geography: U.S. is the sole near-term focus; international expansion is deferred until U.S. market success is validated.

Other Key Points:

• Company has 250 employees, majority based in North and South Carolina.
• Recent scientific presentations at ASN (7 posters, 1 oral) highlighted robust preclinical and translational data supporting the MOA.
• The trial design includes a "true sham" control arm where patients undergo biopsy and sham injection procedures.
• Management anticipates strong interest from nephrologists due to the novelty of the therapy and the lack of alternative treatments for end-stage progression.